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Abstract
Introduction The gene encoding Na+/H+ exchanger regulatory
factor 1 (NHERF1) is a putative tumor suppressor gene that
harbors frequent loss of heterozygosity (LOH) and intragenic
mutations in breast carcinoma. The exact biologic activity of
NHERF1 in mammary glands, however, remains unclear. It was
recently proposed that NHERF1 forms a ternary complex with
platelet-derived growth factor receptor (PDGFR) and
phosphatase and tensin homolog (PTEN), linking NHERF1
suppressor activity to PDGF-initiated phosphoinositide-3 kinase
(PI3K)/PTEN signaling.
Methods The effect of NHERF1 on the kinetics of PDGF-
induced Akt activation was determined in cells with varied
NHERF1 background. Levels of active Akt in mammary gland of
NHERF1 knockout and wild-type mice were compared. We also
examined how NHERF1 expression status affects cell sensitivity
to PDGFR inhibitor. A plausible connection between NHERF1
and PTEN pathway was explored at the genetic level.
Results We showed that NHERF1, through its PDZ-I domain,
interacts directly with the carboxyl-terminal tail of PTEN.
Knocking down NHERF1 expression in Zr75.1 cells markedly
delayed the turnover of PDGF-induced phospho-Akt.
Conversely, NHERF1 over-expression in MCF10A cells led to
accelerated phospho-Akt degradation. The slowed decay of
phospho-Akt that resulted from NHERF1 loss was evident in
mouse embryonic fibroblasts isolated from NHERF1 knockout
mice. In agreement with this, mammary gland tissues from these
mice exhibited markedly elevated phospho-Akt. The responses
of breast cancer cells to PDGFR inhibition were also altered by
changes in NHERF1 expression level. Zr75.1 cells with
NHERF1 knockdown were more resistant to STI-571-induced
apoptosis than parental cells. Similarly, over-expression of
NHERF1 rendered MCF10A cells more sensitive to STI-571.
NHERF1-induced apoptotic response relies on an intact PTEN
pathway; over-expression of NHERF1 in MCF10A cells with
PTEN knockdown did not affect STI-571 sensitivity. It was found
that NHERF1 LOH-positive breast cancer cells had reduced
NHERF1 expression. Interestingly, these cells more frequently
had wild-type PTEN or PI3KCA gene than the LOH-negative
lines.
Conclusion Our data indicate that the interaction of NHERF1
with PTEN counterbalances PI3K/Akt oncogenic signaling and
may affect how cells respond to PDGFR inhibition in breast
cancer. The dependence of NHERF1 responses on PTEN and
genetic segregation of NHERF1  and  PTEN  (or  PI3KCA)
alterations suggest that NHERF1 is an active component of the
PTEN pathway. Collectively, our study indicates that the biologic
activity of NHERF1 in mammary gland is related to PTEN
signaling.
ERM = ezrin-radixin-moesin; GST = glutathione S-transferase; LOH = loss of heterozygosity; MEF = mouse embryonic fibroblast; MTT = 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NHERF = Na+/H+ exchanger regulatory factor; p-Akt = phospho-Akt; PCR = polymerase chain 
reaction; PDGFR = platelet-derived growth factor receptor; PI3K = phosphoinositide-3 kinase; PTEN = phosphatase and tensin homolog; siRNA = 
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Introduction
The gene encoding Na+/H+ exchanger regulatory factor 1
(NHERF1) (also known as EBP-50 or NHERF) is a candidate
tumor suppressor gene in human breast cancer. Human
NHERF1  cDNA encodes a protein of 358 amino acids in
length. NHERF1 and its close homolog NHERF2 (also known
as E3KARP or TKA1) share two modular structures: two tan-
dem PDZ domains at the amino-terminus and an ezrin-radixin-
moesin (ERM)-interacting domain at the carboxyl-terminus [1].
NHERF1 and NHERF2 are differentially expressed in mamma-
lian tissues, with particularly high levels found in polarized epi-
thelial cells [2]. NHERF1 acts as an important regulator and
integrator of multiple signaling pathways by virtue of its ability
to bind to a variety of proteins through its PDZ (PSD-95/Dlg/
ZO1) domains and ERM-interacting domain. Via its PDZ
domains, NHERF1 recognizes a carboxyl-terminal motif, D(S/
T)XL, that is present in a number of transmembrane proteins,
such as platelet-derived growth factor receptor (PDGFR)
[3,4], cystic fibrosis transmembrane conductance regulator
[5-7], β2-adrenergic receptor [8,9], and sodium bicarbonate
co-transporter [10]. NHERF1 also interacts with a variety of
intracellular proteins, including phospholipase C-β isoforms, G
protein-coupled receptor kinase 6A, spleen tyrosine kinase
(SYK) and Yes-associated protein 65 [11-15]. Via its carboxyl-
terminal ERM-interacting domain, NHERF1 binds to ERM pro-
teins, a family of actin cytoskeletal adaptors. One ERM family
member is merlin, the product of NF2 tumor suppressor gene.
Germline mutations of NF2 have been implicated in predispo-
sition to meningiomas and schwanomas [16,17]. The amino-
terminus of the ERM family proteins (ERM domain) binds to
the ERM-interacting domain of NHERF1; this interaction may
be important for NHERF1 functions through its connection of
membrane transporters and actin cytoskeleton.
The NHERF1 gene is located at 17q25.1. Loss of heterozy-
gosity (LOH) at this locus occurs in more than 50% of breast
tumors [15,18-23]. However, such allelic loss is infrequent in
other tumor types; LOH at the NHERF1 locus occurred in
fewer than 10% of colorectal and pancreatic cancer lines,
suggesting that NHERF1 is specifically targeted during breast
tumorigenesis [15]. We reported three cases of NHERF1
intragenic mutations in a panel of breast tumors pre-screened
for LOH [15]; notably, all mutations were located at conserved
residues of PDZ domains or ERM-interacting domain. These
tumorigenic mutations interfere with NHERF1 binding to SYK
or merlin (loss-of-function), suggesting their functional rele-
vance to breast tumor initiation or progression. NHERF1 LOH
positively correlates with aggressive features of breast tumors,
including tumor size, grade and stage, indicating that NHERF1
plays a critical role in mammary carcinogenesis, in which its
putative suppressor activity may be haplo-insufficient.
Despite the genetic evidence available, the biologic activities
of NHERF1 in mammary gland were unknown. The finding that
the phosphorylation status of NHERF1 oscillated during the
cell cycle implicated possible link of NHERF1 to tumor-related
response [24]. Indeed, the fact that NHERF1 is a substrate for
cdc2, a G2 to M phase cyclin-dependent kinase, suggests a
role of NHERF1 in cell division [24]. Using the small interfering
RNA (siRNA) method, we demonstrated increased growth of
breast cancer cells when NHERF1 expression was knocked
down [25]. The growth promotion effect that occurred in
response to NHERF1 loss was due to an accelerated G1 to S
transition, which was accompanied by elevated levels of cyclin
E and phosphorylated Rb protein. This indicated that normal
NHERF1 function may involve suppression of cell cycle pro-
gression [25].
Although the identity of the NHERF1-interacting partner
responsible for the cell cycle regulatory effect remains unclear,
a recent report [26] showed NHERF1 binding to the carboxyl-
terminal tail (PDZ-binding motif) of phosphatase and tensin
homolog (PTEN). The PDZ-binding motif of PTEN was also
shown to interact with membrane-associated guanylate kinase
family proteins, but the biologic significance of these bindings
is not clear [27-29]. The interaction of NHERF1 with PTEN
and PDGFR facilitates the formation of a ternary complex.
Interestingly, this complex formation was found to offset
PDGF-initiated phosphorylation of downstream targets such
as Akt in mouse embryonic fibroblasts (MEFs) [26]. Activated
Akt (by phosphorylation) plays a pivotal role in promoting cell
survival, increasing cell invasiveness and overriding cell cycle
checkpoints [30]. A possible activity of NHERF1 in counter-
acting the Akt pro-oncogenic pathway raises an attractive
mechanism that explains NHERF1 tumor suppressor activity in
mammary glands. Thus, in the present study we sought to
determine whether the activity of NHERF1 is associated with
a PTEN-dependent pathway in breast cells, and whether
NHERF1 expressional status affects PDGF-stimulated down-
stream cell survival signaling as well as cell responses to
PDGFR inhibition.
Materials and methods
Cell culture
Breast cancer cell lines MCF7, MDA-MB-468, SKBr3, T47D,
ZR75.1 and immortalized mammary epithelial line MCF10A
were purchased from American Type Culture Collection (Man-
assas, VA, USA). All cell lines were cultured in recommended
media.
Cultured Zr75.1, MCF10A and MEF cells were incubated with
serum-free media for 1 day. They were then treated with
PDGF-BB (0.5 ng/ml; Millipore, Billerica, MA, USA) for 0 to
120 minutes before cells were harvested in 1× SDS sample
buffer.
NHERF1 knockout mice
NHERF1+/- mice [31] were inbred to generate littermates of
three genotypes. Duplex PCR was used to genotype NHERF1
knockout mice. A common forward primer (5'-ctctgtttattccca-Available online http://breast-cancer-research.com/content/10/1/R5
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gaagga-3') was included in the PCR reaction, together with
reverse primers for knockout (5'-caagctcttcagcaatatcac-3')
and wild-type (5'-ggttctaccagacggataaac-3') genotypes that
were expected to yield 2.4-kilobase and 1.4-kilobase prod-
ucts, respectively. PCR conditions were described previously
[15].
To harvest mammary gland of NHERF1 knockout mice, 10-
week-old female littermates were killed by carbon dioxide inha-
lation. Mammary glands were collected and snap frozen at -
80°C until use. Tissues were then ground while frozen in liquid
nitrogen and lysed in 1× SDS sample buffer. The lysates were
then subjected to immunoblotting.
To obtain MEF cells of varied NHERF1 genetic backgrounds,
the NHERF1+/- mice were inbred. At embryonic days 12 to 14,
the embryos were dissected to remove heads and internal
organs. The remaining tissues were minced, trypsinized and
plated in Dulbecco's medified Eagle's medium supplemented
with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA).
Genomic DNA was also harvested from MEF cells for geno-
typing. Early-passage MEF cells were then subjected to exper-
imental treatment.
DNA constructs
To prepare recombinant retrovirus to knockdown NHERF1
expression, an siRNA sequence that targeted NHERF1 tran-
script was inserted into pBabe-U6-Puro (a gift from Dr Jinsong
Liu, M.D. Anderson Cancer Center, Houston, TX, USA). Two
oligonucleotides (5'-ggaaactgacgagttcttcaaagctttgaagaactc
gtcagtttccctttttg-3' and 5'-aattcaaaaagggaaactgacgagttct
tcaaagctttgaagaactcgtcagtttcc-3') were annealed and sub-
cloned into pBabe-U6, creating pBabe-U6/NHERF-910-Puro.
Similarly, oligonuclotides (5'-ggacgaactggtgtaatgatatgaagct
tcatatcattacaccagttcgtccctttttg-3' and 5'-aattcaaaaagggacga
actggtgtaatgatatgaagcttcatatcattacaccagttcgtcc-3') were
used to knock down PTEN expression (pBabe-U6/PTEN-
Puro).
GST-PTEN, pcDNA3.1-PTEN, and pcDNA3.1-PTEN-C124S
were gifts from Dr Charles Sawyer (University of California,
Los Angeles, CA, USA). To make a PTEN construct with dele-
tion of the last six residues (TQITKV), PCR was conducted to
introduce premature termination, using pcDNA3.1-PTEN as a
template. This procedure created pcDNA3.1-PTEN-ΔC.
NHERF1 cDNA was obtained by reverse transcription from
mRNA of a breast cancer cell line, SKBr3, and amplified by
PCR. Reverse transcription PCR products were subcloned
into a TA cloning vector (Invitrogen). NHERF1 cDNA was then
subcloned into pcDNA3.1(+) (Invitrogen), generating
pDNA3.1-NHERF1. NHERF1 cDNA was then enzymatically
released from pcDNA3.1-NHERF1 and subcloned into
pBabe-Puro, pBabe-Neo (Addgene, Cambridge, MA, USA),
and pGEX2TK (GE Healthcare, Piscataway, NJ, USA), yield-
ing pBabe-NHERF1-Puro, pBabe-NHERF1-Neo, and
pGEX2TK-NHERF1, respectively. cDNA fragments encoding
PDZ-I (residues 1 to 150), PDZ-II (residues 97 to 239), PDZ-
I&II (residues 1 to 239), and carboxyl-terminus (residues 231–
358) of NHERF1 were PCR-amplified and constructed to
pcDNA3.1 or pGEX2TK. All constructs generated by PCR
were verified by automated DNA sequencing.
Retroviral infection
Retroviral stocks were made by transfecting packaging cells
(amphotropic Phoenix cells) with retroviral constructs (pBabe-
U6-Puro, pBabe-U6-NHERF-910-Puro, pBabe-U6-PTEN-
Puro, pBabe-Puro, pBabe-NHERF1-Puro, pBabe-Neo, and
pBabe-NHERF1-Neo), using Fugene 6 (Roche Applied Sci-
ence, Indianapolis, IN, USA).
To prepare MCF10A cells over-expressing NHERF1,
MCF10A cells were infected with NHERF1-Puro (or NHERF1-
Neo for PTEN knockdown cells) recombinant retrovirus.
Infected cells were selected by adding 1 to 5 μg/ml puromycin
(or 600 μg/ml G418) to culture media. Surviving cells were
assessed for NHERF1 expression by immunoblotting.
MCF10A-NHERF1-Neo cells were further infected with
PTEN-siRNA retrovirus to knockdown PTEN expression,
which was determined by PTEN immunoblotting.
The expression of NHERF1 in Zr75.1 and MDA-MB-468 cells
was knocked down by using retrovirus-based siRNA method.
Zr75.1 cells were infected with Babe-U6-NHERF-910-Puro
retrovirus and subjected to puromycin (2 μg/ml) selection.
NHERF1 expression was determined by immunoblotting.
Glutathione S-transferase pull-down assays
Glutathione S-transferase (GST) pull-down assays were used
to assess the interaction of NHERF1 and PTEN. GST-PTEN or
GST-NHERF1 and their derivatives were induced by isopro-
pyl-β-D-1-thiogalactopyranoside  in pGEX2TK-transformed
BL21 strain and purified with glutathione-Sepharose beads
(GE Healthcare).
Radio-labeled full-length or defined segments of NHERF1 and
full-length or truncated PTEN were synthesized by in vitro tran-
scription from pcDNA3.1 plasmids containing the NHERF1 or
PTEN cDNA and translated in the presence of [35S]methio-
nine (T7 Quick TNT kit; Promega, Madison, WI, USA). The
translation products were mixed with purified GST-PTEN or
GST-NHERF1 immobilized on the beads. Pull-down assays
were performed at 4°C for 1 hour in 1× binding buffer (20
mmol/l Tris [pH 7.5], 150 mmol/l NaCl, and 1% NP-40). The
beads were then washed thoroughly with 1× binding buffer.
Bound proteins were eluted by boiling in 1× SDS sample
buffer, separated by SDS-PAGE. Ten per cent of the input
TNT lysates was also run on the PAGE to determine relative
binding capacity. The PAGE gel was then dried and exposed
for autoradiography.Breast Cancer Research    Vol 10 No 1    Pan et al.
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GST pull-down assay was also used to determine whether
endogenous PTEN or NHERF1 binds to recombinant
NHERF1 or PTEN, respectively. MDA-MB-468, MCF7, and
T47D cells were harvested by adding 1× lysis buffer (50
mmol/l Tris-HCl [pH 7.5], 150 mmol/l NaCl, 1 mmol/l EDTA,
1% Triton-X 100, 10 mmol/l NaF, 1 mmol/l Na3VO4 and 1×
protease inhibitor cocktail [Sigma, St. Louis, MO, USA]). The
cell lysates were then incubated with beads coated with GST
fusion proteins. The incubation lasted for 2 hours at 4°C. The
beads were then washed thoroughly with 1× binding buffer
before being boiled in 1× SDS sample buffer. The eluted pro-
teins were then subjected to NHERF1 or PTEN
immunoblotting.
Immunoprecipitation and immunoblotting
To assess the interaction of PTEN with NHERF1 at the endog-
enous level, cultured MCF7 or Zr75.1 cells were lysed with 1×
NETN buffer (20 mmol/l Tris-HCl [pH 7.5], 150 mmol/l NaCl,
1 mmol/l EDTA, 0.5% NP-40, 30 μg/ml aprotinin, 5 mmol/l
PMSF, 25 mmol/l NaF, and 2 mmol/l Na3VO4). The soluble
proteins (about 600 μg) were immunoprecipitated with 2 μg
of goat IgG reactive to PTEN (N-19; Santa Cruz Biotechnolo-
gies, Santa Cruz, CA, USA) at 4°C overnight, using normal
goat IgG as a control. The immunocomplex was collected by
addition of 50 μl of agarose-conjugated protein G (Roche
Applied Science) and detected with anti-NHERF1 antibody.
Protein concentrations were measured by using BCA reagent.
Lysates were then subjected to immunodetection of phospho-
Akt (p-Akt) and total Akt. Immunoblottings were carried out
essentially as described previously [32]. Antibodies used were
human NHERF1 (EXBIO Praha, Vestec, Czech Republic), β-
actin (Santa Cruz Biotechnology), mouse NHERF1 (Affinity
Bioreagents, Golden, CO, USA), PTEN (Millipore), caspase-3,
phospho-Akt-Ser473, total Akt, and phospho-p70 S6 kinase-
Thr421/Ser424 (Cell Signaling Technology, Danvers, MA,
USA).
MTT assays
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide) assays were used to measure cell viability. Cells were
seeded in 96-well cluster dishes at 5,000 cells/well with 100
μl complete medium. After overnight incubation, medium was
replaced to include various concentrations of STI-571
(Novartis Pharmaceuticals). After 2 days of treatment, cells
were fed 100 μl fresh medium that contained 1 mg/ml MTT
(Sigma). The incubation lasted for 2 hours before the medium
was removed and cells dissolved in 150 μl dimethyl sulfoxide.
Absorbance was measured using a multiSkan plate reader
(LabSystems, Waltham, MA, USA) at a wavelength of 570 nm.
Each sample was processed in triplicate. Experiments were
repeated at least three times.
Results
Interaction of NHERF1 and PTEN
To verify that there is an interaction between NHERF1 and
PTEN, we first used GST-PTEN (Figure 1a) to pull down
NHERF1 from lysates of MCF7 and MDA-MB-468 cells. We
found GST-PTEN, but not GST alone, to be associated with
NHERF1 (Figure 1b). Of note, the quantity of full-length GST-
PTEN bound to the beads was much lower than that of the
GST control (Figure 1a). As a result, much less GST-PTEN
was used in the experiments. To determine whether the inter-
action between NHERF1 and PTEN was direct, we conducted
a GST pull-down assay using in vitro synthesized full-length
NHERF1. GST-PTEN but not GST interacted directly with the
full-length NHERF1 and the PDZ-I&II domains (Figure 1c).
Thus, the PDZ-I&II domains of NHERF1 are likely to mediate
this direct interaction. In reverse experiments, we used GST
fusion of PDZ-I and -II domains (residues 1 to 239) or carboxyl-
terminal half (CT; residues 231 to 358) of NHERF1 to pull
down PTEN (Figure 1d). As shown in Figure 1e, GST-PDZ-I&II
bound to PTEN from MCF7 and T47D cell lysates. In contrast,
CT did not bind to PTEN, confirming that NHERF1 interacted
with PTEN through its PDZ domains. To further assess
whether the PDZ-I or the PDZ-II domain was responsible for
PTEN association, we conducted a similar GST pull-down
assay using GST-PDZ-I (residues 1 to 150) or GST-PDZ-II
(residues 97 to 239) beads (Figure 1f). Although PDZ-II did
not interact with PTEN, PDZ-I associated with PTEN at a level
similar to that of PDZ-I&II, indicating that PDZ-I is responsible
for the interaction of NHERF1 with PTEN (Figure 1g).
The direct interaction between PTEN and NHERF1 was also
confirmed by pull-down assays using GST-PDZ and [35S]-
labeled PTEN products. Consistent with earlier findings, the
wild-type PTEN bound strongly to PDZ-I but very weakly to
PDZ-II (Figure 1h). The interaction was not affected by a
tumor-derived mutation (C124S). To determine whether the
PDZ-binding motif in PTEN is required for its interaction with
NHERF1, we made PTEN with a deletion of the last six amino
acids (ΔC). Pull-down assays, showing this PTEN mutant to be
incapable of interacting with NHERF1 (Figure 1h), indicated
that the PDZ-binding motif of PTEN is responsible for its bind-
ing to NHERF1. We further examined whether NHERF1
bound to PTEN at the endogenous expression level by using
MCF7 and Zr75.1 cells that expressed high levels of NHERF1
and PTEN. Co-immunoprecipitation identified a significant
interaction between the two proteins, demonstrating that
NHERF1 associates with PTEN in vivo when they are
expressed at the endogenous level (Figure 1i).
NHERF1 affects cell responses to PDGF-initiated Akt 
phosphorylation
Expression of NHERF1 reportedly accelerates the decay of p-
Akt induced by PDGF stimulation. We first verified this conclu-
sion in NHERF1+/+ and NHERF1-/- MEFs isolated from 14-day
embryos that resulted from crossing of NHERF1+/- mice. TheirAvailable online http://breast-cancer-research.com/content/10/1/R5
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NHERF1 genetic status was determined by genotyping, and
their NHERF1 protein expression was verified by immunoblot-
ting (Figure 2a). NHERF1-/- and NHERF1+/+ MEFs were then
subjected to treatment with PDGF ligands and harvested after
0 to120 minutes. PDGF initially induced p-Akt to similar levels
in the two groups of MEFs (10 minutes). p-Akt in NHERF1-/-
cells remained at high levels at 90 and 120 minutes, but the p-
Akt level in NHERF1+/+ cells deminished markedly (Figure 2b).
We repeated these experiments in two cell lines of breast ori-
gin. MCF10A cells over-expressing NHERF1 cDNA by retro-
viral infection exhibited a faster turnover of p-Akt than did
control cells (Figure 3a). Likewise, knockdown of NHERF1
expression in Zr75.1 cells by retroviral infection with NHERF-
910 siRNA decelerated the decay of p-Akt signals induced by
PDGF (Figure 3b). In agreement with these findings, the phos-
phorylation status of an Akt downsream target, namely p70 S6
kinase, was consistent with p-Akt level in both MCF10A and
Zr75.1 cells. These results agree with the working model that
Figure 1
The PDZ-binding motif of PTEN associates with the PDZ-I domain of NHERF1 The PDZ-binding motif of PTEN associates with the PDZ-I domain of NHERF1. (a) Coomassie-blue staining of glutathione S-transferase (GST)-
phosphatase and tensin homolog (PTEN) fusion (arrow) and GST control protein. (b) GST pull-down assays. GST-PTEN beads were incubated with 
MCF7 or MDA-MB-468 cell lysates. The protein bound on beads was separated by SDS-PAGE and subjected to Na+/H+ exchanger regulatory fac-
tor 1 (NHERF1) immunoblotting. Ten per cent of the initial protein input was run side-by-side. (c) GST pull-down. The full-length NHERF1 or the 
PDZ-I&II domain protein was synthesized by TNT reaction in the presence of [35S]methionine. The labeled proteins were then incubated with GST or 
GST-PTEN. Components bound to GST fusion were separated by SDS-PAGE and detected by autoradiography. (d) Coomassie-blue staining of 
GST fusion of PDZ-I&II or the carboxyl-terminal half (CT) of NHERF1. (e) GST pull-down. Procedures were the same as those described for panel b 
except that MCF7 and T47D cells lysates, GST-PDZ-I&II and GST-CT were used in the reaction. Bound protein was detected by PTEN immunoblot-
ting. (f) Coomassie-blue staining of GST fusion of PDZ-I or PDZ-II compared with that of PDZ-I&II. (g) NHERF1 interaction with PTEN through its 
PDZ-I domain. The experimental method was the same as that described for panel e except for the use of GST-PDZ-I and GST-PDZ-II. (h) PTEN 
binding to NHERF1 through its carboxyl-terminal PDZ-binding motif. 35S-labeled wild-type (WT) PTEN, a tumorigenic mutant (C124S), or a PTEN 
variant with deletion of the PDZ motif (delta C) were made by TNT reaction and evaluated for their binding to PDZ-I or PDZ-II of NHERF1. (i) Lysates 
from MCF7 and Zr75.1 cells were subjected to immunoprecipitation using anti-PTEN antibody or normal goat IgG. The NHERF1 protein was 
detected in the precipitated materials by immunoblotting. Twenty per cent of input lysates was run side-by-side.Breast Cancer Research    Vol 10 No 1    Pan et al.
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NHERF1 attenuates PDGF-initiated downstream survival sig-
nals by forming protein complex with PTEN and PDGFR.
Higher level of p-Akt in mammary tissues of NHERF1 
knockout mice
Knockout or knockdown of NHERF1 resulted in slower
dephosphorylation of Akt in vitro (Figures 2 and 3). If this
occurs in vivo as well, then an increase in p-Akt level would be
expected in the NHERF1 knockout mice. To clarify this, we
measured the p-Akt level in mammary gland specimens taken
from the three groups of mice (NHERF1+/+, NHERF1+/-, and
NHERF1-/-), whose NHERF1 genetic background was verified
(Figure 4a). NHERF1 protein was also measured. Despite
expressional variability among mice in the same group,
NHERF1+/- mice had an overall lower NHERF1 protein level in
mammary glands than did wild-type mice. No NHERF1 protein
was detectable in the NHERF1-/- mice (Figure 4b). This finding
was consistent with the NHERF1 expression pattern in kidney
extracts among the three genotypes [31]. When p-Akt was
measured, the NHERF1-/- mammary gland was shown to main-
tain a markedly higher p-Akt level in comparison with that of
the  NHERF1+/+  specimens, whereas the total Akt level
remained little changed (Figure 4b). This result suggests that
normal NHERF1 function involves suppression of Akt survival
signaling by affecting the balance between PI3K and PTEN.
Interestingly, compared with the wild-type mice, the
NHERF1+/- mice exhibited a moderate but consistent increase
in p-Akt level (Figure 4b), indicating that decreased NHERF1
expression resulting from deletion of a single NHERF1 allele
may be sufficient to promote cell survival in the mammary
gland.
NHERF1 affects cell sensitivity to PDGFR inhibitor
Because NHERF1 markedly affected p-Akt turnover in
response to PDGF stimulation, we surmised that NHERF1
Figure 2
NHERF1 deletion leads to increased stability of PDGF-stimulated p-Akt  signal in mouse embryonic fibroblasts NHERF1 deletion leads to increased stability of PDGF-stimulated p-Akt 
signal in mouse embryonic fibroblasts. (a) Genotyping and Na+/H+ 
exchanger regulatory factor 1 (NHERF1) expression of mouse embry-
onic fibroblast (MEF) cells with NHERF1+/+ and NHERF1-/- back-
grounds. Left panel: duplex PCR was conducted to evaluate the 
genotypes, using the genomic DNA extracted from MEFs. Wild-type 
(WT) and knockout (Neo) alleles were expected to generate 1.4-kilo-
base and 2.4-kilobase products, respectively. Predicted genotypes are 
indicated. Right panel: NHERF1 expression in MEFs as measured by 
immunoblotting. Asterisks indicate bands from nonspecific reactivity to 
mouse NHERF1 antibody. (b) MEFs (NHERF1+/+ or NHERF1-/-) were 
serum starved and stimulated with platelet-derived grwoth factor-BB 
(0.5 ng/ml) for indicated periods before cells were harvested for phos-
pho-Akt (p-Akt; Ser473) measurement. Total Akt was also measured to 
verify equivalent loading.
Figure 3
NHERF1 accelerates decay of p-Akt induced by PDGF NHERF1 accelerates decay of p-Akt induced by PDGF. (a) MCF10A 
cells over-expressing Na+/H+ exchanger regulatory factor 1 (NHERF1) 
or control vector (Babe) were serum starved and restimulated with 
platelet-derived growth factor for 0 to 120 minutes as indicated. Cells 
were lysed for measurement of phospho-Akt (p-Akt) level by immunob-
lotting. Expression status of NHERF1 was verified. Total Akt was also 
determined to normalize loading. (b) Zr75.1 cells infected with 
NHERF1 knockdown vector (910) or control (Babe) were analyzed as 
described for panel a.Available online http://breast-cancer-research.com/content/10/1/R5
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expression status might also affect cell response to PDGFR
inhibition. Zr75.1 cells with or without NHERF1 knockdown
were treated with STI-571 for 2 days before MTT assay for sur-
viving cells. STI-571 is a small molecule inhibitor of tyrosine
kinases, including BCR-Abl, PDGFR and c-kit, and as a result
it has been used effectively in patients with chronic myeloge-
nous leukemia, gastrointestinal stromal tumor, and other types
of tumors [33-35]. We first compared the Zr75.1 cells (base
control and NHERF1 knockdown cells) in tems of their sensi-
tivity to STI-571. While untreated, NHERF1 knockdown cells
exhibited a modest increase in cell proliferation after 2 days of
culture, which is in agreement with our earlier report [25].
When cells were treated with STI-571, we found that Zr75.1
cells with NHERF1 knockdown were much more resistant to
STI-571 than the control (Figure 5a). Similarly, over-expres-
sion of NHERF1 in MCF10A cells rendered them more sensi-
tive to STI-571 treatment than their corresponding Babe
control (Figure 5b). These findings suggest that changes in
cell survival signaling resulting from NHERF1 loss affect cell
sensitivity to PDGFR blocker.
To determine whether apoptosis is involved in the cell density
difference between NHERF1-positive and NHERF1-negative
cells, we harvested the cells during STI-571 treatment and
assayed cell lysates for cleaved forms of caspase-3, a marker
of active apoptotic process. Immunoblottings showed that
before STI-571 treatment, no cleaved caspase-3 isoforms
were present in either the NHERF1 knock-down or the control
Zr75.1 (Babe) cells. One day of STI-571 treatment resulted in
significant increases in caspase-3 cleavage in Zr75.1 Babe
control cells, suggesting that apoptosis is at least partially
responsible for STI-571-induced growth inhibition. Interest-
ingly, the same treatment led to markedly lower caspase-3
cleavage in NHERF1-knockdown Zr75.1 cells (Figure 6a),
which is consistent with a decreased response to STI-571-
induced cell death in comparison with that of NHERF1-posi-
tive Zr75.1 cells (Figure 5a). Similar experiments were carried
out on MCF10A cells, in which we showed that over-expres-
sion of NHERF1 markedly enhanced STI-571-induced cleav-
age of caspase-3 (Figure 6b). All of these findings indicated
that loss of NHERF1 may affect cell response to growth factor
inhibition as a result of increases in intrinsic cell survival [36].
To assess whether PTEN is required for the increased sensi-
tivity to STI-571, we first determined whether altered NHERF1
expression level affected cell responses to STI-571 in a PTEN-
null background. MDA-MB-468 cells are NHERF1 positive but
lack PTEN as a result of homozygous deletion. We knocked
down NHERF1 expression in MDA-MB-468 cells using siRNA
retrovirus, and these cells were tested for STI-571 sensitivity.
We found that in the absence of PTEN the NHERF1-knock-
down cells responded to STI-571 at a level similar to that in
Babe control cells (Figure 7a). We then determined whether
PTEN knockdown was able to influence NHERF1-inducible
sensitivity to STI-571 in MCF10A cells. NHERF1 expression
(or Neo control) in MCF10A cells was retrovirally transduced
and the resultant cells were subjected to PTEN knockdown
through retrovirally delivered siRNA (or Babe control). These
steps yielded four cell lines with varying PTEN and NHERF1
expression. These cells were then tested for STI-571 sensitiv-
ity. PTEN knockdown resulted in a modest increase in prolifer-
ation as compared with the control. As expected, over-
expression of NHERF1 in parental cells elevated STI-571-
inducible killing. In contrast, NHERF1 expression in cells with
PTEN knockdown remained highly resistant to STI-571. These
findings indicated that increased sensitivity to PDGFR inhibi-
tion by NHERF1 was dependent on PTEN (Figure 7b).
LOH is correlated with lowered NHERF1 expression and 
wild-type PTEN or PI3KCA
To explore whether LOH is responsible for a decrease in
NHERF1 expression, we correlated the two parameters in 22
breast cancer cell lines that had been tested [15,25]. Among
the six cell lines with a high NHERF1 expression level, five
(83%) were found to be LOH negative. In contrast, of the 16
cell lines with low and no NHERF1 expression, only two
(12.5%) were LOH negative. Thus, LOH at the NHERF1 locus
is highly associated with lowered NHERF1 expression (P =
6.8 × 10-6, by Fisher's exact test).
Figure 4
Elevated phospho-Akt levels in mammary gland of NHERF1 knockout  mice Elevated phospho-Akt levels in mammary gland of NHERF1 knockout 
mice. (a) Genotyping of NHERF1 knockout mice. Numbers 1 to 3, 4 to 
6, and 7 to 9 represent NHERF1+/+, NHERF1+/-, and NHERF1-/- mice, 
respectively. (b) Immunodetection of NHERF1 and phospho-Akt (p-Akt; 
Ser473) expression in mammary gland tissues from mice of respective 
genotypes. Membrane was stripped and reprobed with β-actin to nor-
malize loading. WT, wild-type.Breast Cancer Research    Vol 10 No 1    Pan et al.
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The physical and functional relation between NHERF1 and
PTEN indicates they may exist in a common tumor suppressor
pathway, which would predict segregation between NHERF1
and  PTEN  (or  PI3KCA) alterations. We thus evaluated
whether  NHERF1  LOH is correlated with PTEN/PI3KCA
mutational status. A total of 39 breast cancer cell lines with
available genetic status were used for the correlative analyses
[37]. Among the 23 NHERF1  LOH-positive cell lines, 15
(65%) had an unaltered PTEN or PI3KCA gene. In contrast,
out of the 16 LOH-negative cell lines, only 4 (25%) showed
wild-type  PTEN/PI3KCA  status. The genetic alteration in
either PTEN or PI3KCA gene was strongly associated with
intact NHERF1 alleles (P = 0.022, by Fisher's exact test).
Discussion
Our earlier results of NHERF1genetic alterations in human
breast cancer prompted us to hypothesize that NHERF1 acts
as a tumor suppressor gene in mammary gland [15]. Human
NHERF1  is an estrogen-inducible gene [36]. Estrogen
response element half-sites have been located in the 5'-regu-
latory region of NHERF1 gene that are responsible for estro-
gen-stimulated expression [38]. Because estrogenic signaling
is thought to be growth promoting in breast cancer [39], the
suppressor activity of NHERF1 was somewhat unexpected.
Although the roles of estrogenic induction in NHERF1 biology
is not clear, we identified increased growth of breast cancer
cells after NHERF1 knockdown [25], which is in agreement
with the proposed tumor suppressor function of NHERF1.
Here we provide additional evidence to support our overall
hypothesis.
In breast cells, NHERF1 expression accelerated the turnover
of p-Akt induced by PDGF stimulation. This finding was
obtained in both over-expression and knockdown models,
from both immortalized normal mammary epithelial cells
(MCF10A) and a breast cancer line (Zr75.1). The effect of
NHERF1 to stimulate the decay of p-Akt is probably through
PTEN recruitment by NHERF1 to the cytoplasmic membrane
compartment, where active phosphorylation and dephosphor-
ylation of Akt occur. The response is probably related to nor-
mal mammary biology, as indicated by the markedly increased
levels of p-Akt in the mammary gland tissues of NHERF1-/-
mice (Figure 4). Elevated p-Akt resulting from NHERF1 dele-
tion presumably potentiates the cell survival pathway in mam-
mary gland, where balanced survival and apoptotic signaling is
essential for normal development and homeostasis [40]. A
deregulated apoptotic process, which leads to defective
structural organization and remodeling in mammary gland, is
believed to be directly related to breast cancer etiology
[41,42]. Interestingly, we recently found that, in contrast to the
wild-type mice, NHERF1-/- mice exhibited increased ductal
side branching and extensive alveolar hyperplasia in mammary
gland (our unpublished data). Whether aberrant Akt activation
is directly related to hyperplastic morphology in mammary
gland warrants further investigation. Also remaining to be
established is whether this impaired mammary development is
sufficient to increase or accelerate the incidence of mammary
tumor.
Because of the strong correlation between NHERF1 LOH and
the aggressive features of breast cancer, we hypothesized
Figure 5
NHERF1 increases cell sensitivity to STI-571 NHERF1 increases cell sensitivity to STI-571. (a) Zr75.1 cells with NHERF1 knockdown (910) or Babe controls were cultured in 96-well plates and 
treated with STI-571 (10 and 30 μmol/l) for 2 days. (b) MCF10A cells over-expressing Na+/H+ exchanger regulatory factor 1 (NHERF1) or vector 
control were subjected to STI-571 treatment (3 and 10 μmol/l) for 2 days. MTT reagents were added to assess the relative number of surviving cells. 
The numbers of untreated Babe control were arbitrarily set at 100%. Data from five independent experiments are presented. **P < 0.01, ***P < 
0.001 versus Babe control of the corresponding treatment.Available online http://breast-cancer-research.com/content/10/1/R5
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that NHERF1 tumor suppressor activity was haploinsufficient
[15]. A number of tumor suppressor genes have been shown
to have haploinsufficient activities [43-46]. In these cases,
mice carrying an inactivated allele are predisposed to tumor
development, and the resulting tumors frequently retain a func-
tional wild-type allele. Interestingly, two NHERF1-binding part-
ners, namely PTEN and NF2, use this mechanism [43,44]. A
lowered expression as a result of single allele deletion of the
NHERF1 gene is obligatory for its haploinsufficient biology. In
support of this mechanism, we found that LOH of NHERF1
locus in 22 breast cancer cell lines was strongly correlated
with lowered NHERF1 protein level. The haploinsufficient
expression of NHERF1 is also supported by in vivo observa-
tions. Monoallelic deletion of NHERF1  was shown to
decrease NHERF1 expression in kidney epithelial cells [31].
Similarly, deletion of one allele of the NHERF1 gene resulted
in decreased NHERF1 protein expression in mammary gland
(Figure 4), providing a plausible link between altered protein
expression level and the resultant phenotypic responses. We
found lowered NHERF1 expression to be accompanied by a
modest increase in p-Akt in the mammary tissue of NHERF1+/
- mice as compared with that in wild-type (Figure 4). Coinci-
dentally, the mammary glands of NHERF1+/- mice exhibited
alveolar hyperplasia, albeit less extensively than the NHERF1-
/- mice (our unpublished data). The correlation suggested an
association between abnormal Akt activation and mammary
hyperplasia, highlighting the biochemical and pathological
consequences of monoallelic deletion of NHERF1.
Our findings clearly indicated a dosage effect of NHERF1
activity during normal mammary gland development. Whether
NHERF1 affects breast cancer susceptibility through the hap-
loinsufficiency mechanism requires further investigation. Hap-
loinsuficient NHERF1 tumor suppressor activity would also
explain the relatively low frequency of intragenic mutations,
although the possibility that other NHERF1 pathway compo-
nents are genetically altered cannot be ruled out.
The present study verifies that NHERF1 has tumor suppressor
activity, providing evidence to suggest that its function relies
on an intact PTEN pathway. First, NHERF1 is associated with
accelerated dephosphorylation of p-Akt, presumably through
recruitment of PTEN by NHERF1. Second, knockdown of
PTEN abolishes NHERF1-induced sensitivity to chemo-
agents. If NHERF1 activity is dependent on PTEN, as our func-
tional study had suggested, then intact NHERF1 should be
associated with altered PTEN (or PI3KCA) gene in breast
cancer. Our data from 39 breast cancer cell lines showed that
this was indeed the case. Collectively, our present study indi-
cates that NHERF1 binds to PTEN to downregulate the PI3K-
Akt pathway to elicit tumor suppressor activity. Given that
PTEN-PI3K-Akt is one of the most prominent pathways rele-
vant to tumorigenesis and targeted therapy of almost all types
of carcinoma, studies on NHERF1 should be instrumental to
the development of new strategies to overcome chemo-resist-
ance and enhance efficacy.
In this study we also present evidence that NHERF1 expres-
sion status significantly affects how cells respond to PDGFR
inhibition. PDGF is among the key growth factors and
cytokines that breast cancer cells produce via autocrine or
paracrine mechanisms that contribute to malignant progres-
sion [47]. Activated PDGF signaling has been shown to pre-
vent cells from undergoing apoptosis during epithelial
mesenchymal transition and thus promote breast cancer pro-
gression and metastasis [48,49]. As a potent PDGFR
inhibitor, STI-571 has been shown to inhibit breast cancer
bone metastasis in mouse models [50], and it is being tested
clinically in treatment of metastatic breast cancer, among other
cancer types [51]. Although the exact mechanism responsible
for improved susceptibility to STI-571 by NHERF1 needs fur-
ther investigation, our present study indicates an inhibitory
effect of NHERF1 on PDGF-medicated breast cancer pro-
gression and suggests that the status of NHERF1 expression
in breast tumor influences how patients respond to STI-571.
Because a majority of breast tumors lose NHERF1 expression,
our present study raises a possibility of enhancing chemosen-
sitivity by restoring NHERF1 expression. NHERF1 expression
may also be used as a biomarker to predict the effectiveness
of such treatment.
Conclusion
In this report, we show that, by interacting with PTEN,
NHERF1 accelerates the turnover of p-Akt and enhances the
cell sensitivity to STI-571. That NHERF1 elicits suppressor
function through PTEN is also indicated by an inverse correla-
tion between intact NHERF1 gene and wild-type PTEN or
PI3KCA in breast cancer cells. Given the critical roles of Akt
in cell survival and tumorigenesis, the negative regulatory
Figure 6
NHERF1 increases caspase-3 cleavage in response to STI-571 NHERF1 increases caspase-3 cleavage in response to STI-571. Cul-
tured (a) MCF10A and (b) Zr75.1 cells of varying Na+/H+ exchanger 
regulatory factor 1 (NHERF1) expression level were treated with STI-
571 for 1 day. Cells were then lysed and separated by SDS-PAGE. 
Immunoblotting was used to detect caspase-3 (8G10). The caspase-3 
antibody recognized both the full-length (35 kDa [arrow]) and the large 
fragment (17/19 kDa [arrowhead]) of caspase-3 resulting from 
cleavage.Breast Cancer Research    Vol 10 No 1    Pan et al.
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effect of NHERF1 on Akt activity is highly relevant to NHERF1
mammary tumor suppressor function. Our finding of a higher
sensitivity of breast cells to STI-571 in the presence of
NHERF1 suggests that future investigations of this important
pathway may yield new measures to improve breast cancer
treatment.
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